Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia

Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection

Research

Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate

These results contribute to our understanding of immunopathology associated with visceral leishmaniasis and response to sodium stibogluconate treatment

Research

Using record linkage to validate notification and laboratory data for a more accurate assessment of notifiable infectious diseases

Studies investigating pathogen-specific infectious disease would benefit from using multiple data sources.

Research

Otitis-prone children produce functional antibodies to pneumolysin and pneumococcal polysaccharides

The production of functional antipneumococcal antibodies in otitisprone children demonstrates that they respond to the current pneumococcal conjugate vaccine (PCV)and are likely to respond to pneumolysin-based vaccines as effectively as healthy children.

Research

Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines

Systematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations

Research

The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyoderma

We conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.

Research

Measles

Measles is a highly contagious infectious disease that can cause severe, long-term complications in children.

Research

Convalescent plasma in hospitalised patients with COVID-19

Convalscent plasma (CP) was identified as a potential therapy for COVID-19 available early in the pandemic.

Research

Global risk of selection and spread of Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions

Since their first detection in 2010, Plasmodium falciparum malaria parasites lacking the P. falciparum histidine-rich protein 2 gene (pfhrp2) have been observed in 40 of 47 surveyed countries, as documented by the World Health Organization. These genetic deletions reduce detection by the most widely used rapid diagnostic tests, prompting three countries to switch to alternative diagnostics.